Save your place

Sign in to WhoBought

Please try again later.

Keros Therapeutics, Inc. (KROS) institutional ownership

Latest close $10.57 Jul 21, 2026
Market cap$582M 52-week range SectorHealthcare
Funds holding · Q1 2026
164
reported KROS position changes
Top owners · Q1 2026
No disclosed owners are available.
Institutional activity · Q1 2026
Activity unavailable N/A
71 buyers · 93 sellers

Keros Therapeutics, Inc. (KROS) price and institutional activity

Dates

Q1 2026

$0 bought by 71 investors
Nantahala Capital Management, LLCDimensional +69 more
$0 sold by 93 investors
Arrowstreet Capital, Limited PartnershipState Street +91 more
Bought Sold Totals per quarter; hover a bar for the names.

Keros Therapeutics, Inc. (KROS) institutional activity · 93

Investor Type Est. change Change Δ Own Date
Arrowstreet Capital, Limited Partnership · Reduced
Change −744K Date Q1 2026
Arrowstreet Capital, Limited Partnership Reduced· Q1 2026 −744K Q1 2026
State Street · Reduced
Change −514K Date Q1 2026
State Street Reduced· Q1 2026 −514K Q1 2026
Goldman Sachs Group Inc · Reduced
Change −366K Date Q1 2026
Goldman Sachs Group Inc Reduced· Q1 2026 −366K Q1 2026
Weiss Asset Management LP · Exited
Change −254K Δ Own −100.0% Date Q1 2026
Weiss Asset Management LP Exited· Q1 2026 −254K −100.0% Q1 2026
D. E. Shaw & Co., Inc. · Reduced
Change −246K Δ Own −32.5% Date Q1 2026
D. E. Shaw & Co., Inc. Reduced· Q1 2026 −246K −32.5% Q1 2026
Madison Avenue Partners, LP · Reduced
Change −197K Date Q1 2026
Madison Avenue Partners, LP Reduced· Q1 2026 −197K Q1 2026
Algert Global LLC · Exited
Change −194K Δ Own −100.0% Date Q1 2026
Algert Global LLC Exited· Q1 2026 −194K −100.0% Q1 2026
Hrt Financial LP · Reduced
Change −184K Date Q1 2026
Hrt Financial LP Reduced· Q1 2026 −184K Q1 2026
Two Sigma Advisers, LP · Exited
Change −172K Δ Own −100.0% Date Q1 2026
Two Sigma Advisers, LP Exited· Q1 2026 −172K −100.0% Q1 2026
Nomura Holdings Inc · Exited
Change −157K Δ Own −100.0% Date Q1 2026
Nomura Holdings Inc Exited· Q1 2026 −157K −100.0% Q1 2026
Deutsche Bank AG · Reduced
Change −145K Date Q1 2026
Deutsche Bank AG Reduced· Q1 2026 −145K Q1 2026
Renaissance Technologies LLC Reduced· Q1 2026 −138K −23.4% Q1 2026
Jane Street Group, LLC · Reduced
Change −118K Date Q1 2026
Jane Street Group, LLC Reduced· Q1 2026 −118K Q1 2026
Millennium Management LLC · Reduced
Change −113K Date Q1 2026
Millennium Management LLC Reduced· Q1 2026 −113K Q1 2026
Jump Financial, LLC · Reduced
Change −111K Date Q1 2026
Jump Financial, LLC Reduced· Q1 2026 −111K Q1 2026
Data through Q1 2026 · filed Jun 2, 2026
15 of 93

Famous investor activity in Keros Therapeutics, Inc. (KROS)

Keros Therapeutics, Inc. (KROS) insider trading

Company insiders, action and economics first; trade and filed dates last.
Dates
Insider Title Type Price Qty Value Owned ΔOwn Trade date Filed date
Bienaime Jean Jacques · Director Buy +$11K
Price $10.61 Qty +1K Owned 19K ΔOwn +5.7% Trade date Jul 15, 2026 Filed date Jul 17, 2026
Bienaime Jean Jacques Director Buy $10.61 +1K +$11K 19K +5.7% Jul 15, 2026 Jul 17, 2026
Prener Anne · Director 2 operations 29K
Owned 15K Trade date Jul 1, 2026 Filed date Jul 6, 2026
Prener Anne Director 2 operations 29K 15K Jul 1, 2026 Jul 6, 2026
Bienaime Jean Jacques · Director Buy +$10K
Price $10.19 Qty +1K Owned 18K Trade date Jun 15, 2026 Filed date Jun 17, 2026
Bienaime Jean Jacques Director Buy $10.19 +1K +$10K 18K Jun 15, 2026 Jun 17, 2026
Newton Charles W. · Director Sell −$6K
Price $10.04 Qty −550 Owned 13K Trade date Jun 11, 2026 Filed date Jun 15, 2026
Newton Charles W. Director Sell $10.04 −550 −$6K 13K Jun 11, 2026 Jun 15, 2026
Farzan Nima · Director Sell −$28K
Price $10.73 Qty −3K Owned 10K Trade date Jun 4, 2026 Filed date Jun 8, 2026
Farzan Nima Director Sell $10.73 −3K −$28K 10K Jun 4, 2026 Jun 8, 2026
Knowles Julius · Director Sell −$28K
Price $10.73 Qty −3K Owned 11K Trade date Jun 4, 2026 Filed date Jun 8, 2026
Knowles Julius Director Sell $10.73 −3K −$28K 11K Jun 4, 2026 Jun 8, 2026
Seth Alpna · Director Sell −$28K
Price $10.72 Qty −3K Owned 10K Trade date Jun 4, 2026 Filed date Jun 5, 2026
Seth Alpna Director Sell $10.72 −3K −$28K 10K Jun 4, 2026 Jun 5, 2026
Seth Alpna · Director 2 operations 15K
Owned 7K Trade date Jun 3, 2026 Filed date Jun 5, 2026
Seth Alpna Director 2 operations 15K 7K Jun 3, 2026 Jun 5, 2026
Gray Mary Ann · Director 2 operations 15K
Owned 7K Trade date Jun 3, 2026 Filed date Jun 5, 2026
Gray Mary Ann Director 2 operations 15K 7K Jun 3, 2026 Jun 5, 2026
Farzan Nima · Director 2 operations 15K
Owned 7K Trade date Jun 3, 2026 Filed date Jun 5, 2026
Farzan Nima Director 2 operations 15K 7K Jun 3, 2026 Jun 5, 2026
Bienaime Jean Jacques · Director 2 operations 15K
Owned 7K Trade date Jun 3, 2026 Filed date Jun 5, 2026
Bienaime Jean Jacques Director 2 operations 15K 7K Jun 3, 2026 Jun 5, 2026
Knowles Julius · Director 2 operations 15K
Owned 7K Trade date Jun 3, 2026 Filed date Jun 5, 2026
Knowles Julius Director 2 operations 15K 7K Jun 3, 2026 Jun 5, 2026
Bienaime Jean Jacques · Director Buy +$11K
Price $10.58 Qty +1K Owned 9K Trade date May 15, 2026 Filed date May 19, 2026
Bienaime Jean Jacques Director Buy $10.58 +1K +$11K 9K May 15, 2026 May 19, 2026
Bienaime Jean Jacques · Director Buy +$12K
Price $11.70 Qty +1K Owned 8K Trade date Apr 15, 2026 Filed date Apr 17, 2026
Bienaime Jean Jacques Director Buy $11.70 +1K +$12K 8K Apr 15, 2026 Apr 17, 2026
Seehra Jasbir · Director 2 operations 0
Price $0.30 Owned 197K Trade date Apr 2, 2026 Filed date Apr 6, 2026
Seehra Jasbir Director 2 operations $0.30 0 197K Apr 2, 2026 Apr 6, 2026
15 of 32
15 of 32 Sign in to continue to older insider transactions.

Keros Therapeutics, Inc. (KROS) activist and large shareholders

Dates
Owner/Filer identity Shares reported % of shares outstanding Filing date
FMR LLC 3.9M
% of shares outstanding 12.9% Filing date Feb 9, 2024
FMR LLC 3.9M 12.9% Feb 9, 2024
Nantahala Capital Management, LLC 1.4M
% of shares outstanding 6.9% Filing date May 15, 2026
Nantahala Capital Management, LLC 1.4M 6.9% May 15, 2026
BlackRock Inc. 2.0M
% of shares outstanding 6.8% Filing date Jan 26, 2024
BlackRock Inc. 2.0M 6.8% Jan 26, 2024
BlackRock Portfolio Management LLC 1.1M
% of shares outstanding 5.7% Filing date Jul 17, 2026
BlackRock Portfolio Management LLC 1.1M 5.7% Jul 17, 2026
Alkeon Capital Management LLC 1.5M
% of shares outstanding 5.0% Filing date Feb 13, 2024
Alkeon Capital Management LLC 1.5M 5.0% Feb 13, 2024
Arkin Moshe 1.4M
% of shares outstanding 5.0% Filing date Feb 2, 2023
Arkin Moshe 1.4M 5.0% Feb 2, 2023
Orbimed Advisors LLC 1.3M
% of shares outstanding 4.2% Filing date Dec 13, 2023
Orbimed Advisors LLC 1.3M 4.2% Dec 13, 2023
Deep Track Capital, LP
% of shares outstanding 0.0% Filing date Feb 14, 2023
Deep Track Capital, LP 0.0% Feb 14, 2023
8 of 9

Keros Therapeutics, Inc. (KROS) ownership FAQ

Who owns KROS?

164 reporting institutions disclosed KROS position changes in the Q1 2026 snapshot.

How is institutional activity calculated?

For each manager, WhoBought compares accepted consecutive 13F share counts. Share change is current shares minus prior shares. Estimated dollar change is that signed share change multiplied by the split-adjusted quarter-mean close. The activity table on this page uses Q1 2026.

What are activist and large shareholder filings?

An investor crossing 5% of a share class generally files Schedule 13D for activist intent or Schedule 13G for a passive position. The technical form names appear here rather than in the activity rows.

Where does this data come from?

Ownership and institutional activity come from SEC Form 13F filings. Insider activity comes from SEC Form 4, and large-shareholder activity from SEC Schedules 13D and 13G. FMP supplies price data only. Company logos use the local verified Parqet cache with one shared fallback.

Why are ownership reports delayed?

Form 13F is a quarterly disclosure and is normally filed after the quarter ends. Every ownership and activity value therefore names its represented period; it is not presented as a live position.

How are missing table values shown?

A muted dash marks a missing table value. It means the filing omitted the value, comparable data is unavailable, or no prior position exists for comparison.